• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Nascent Biotech News

antibody-600
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

July 19, 2022  Science News

VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

0
Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma

Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma

June 14, 2022  Corporate News
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

June 7, 2022  Science News
Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

May 4, 2022  Corporate News, News
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

April 12, 2022  News, Press Releases
Load More

Delivering human antibodies for the treatment of cancer

© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.